

Response to Review Comments

Manuscript Title	Current status of first-line therapy, anti-angiogenic therapy and its combinations of other agents for unresectable hepatocellular carcinoma
Manuscript Number	64343
Journal	World Journal of Gastrointestinal Oncology
Authors	Saleh A. Alqahtani, Massimo Colombo
Comments Received	15 Mar 2021
Revision Submitted	24 Mar 2021

S. No.	Section / Content	Comment	Response
Reviewer 1			
1	General / Language	This review paper is interesting. I have no other comment. But, minor language polishing is needed.	Thanks for the comment. We have subjected the manuscript to language polishing to make it read better. English editing certificate has been attached separately.
Reviewer 2			
2	General / Language	<p>This is a revised version review on therapeutic drugs for unresectable HCC. The manuscript is concisely reviewed and well written.</p> <p>I only point out some mistakes as follows: 1. p10 line19 real-life world → real-world 2. p15 line7 partialresponse → partial response 3. p16 line6 progressive → progression</p>	Thank you very much for the comment. We have made all the changes.

S. No.	Section / Content	Comment	Response
Reviewer 3			
3	Lenvatinib failure	<p>Thank you for your great thesis. I'd like to ask you one point.</p> <p>I'd like to have a reference to the secondary drug after the first targeted treatment failure. I think regorafenib, cabozantinib will need to comment. Thank you for your hard work.</p>	<p>Thanks for your viewpoint. We have included the following texts on page 16:</p> <p>“As of date, there are no standard treatment options available for patients who encountered lenvatinib failure. Sorafenib can be considered in such cases, given that about one-fourth of patients in the REFLECT trial received sorafenib while taking lenvatinib as the first-line medication^[38]. Recently, a Japanese pilot study has suggested the potential therapeutic benefit from ramucirumab after lenvatinib failure in HCC patients; nevertheless, another study with more patients could not confirm such benefits in the post-progression treatment^[39, 40].”</p>
Science Editor			
4	Author Contributions Section	The “Author Contributions” section is missing. Please provide the author contributions	Thanks for the comment. We have now added the authorship contributions and other relevant sections stated in the guidelines and requirements for manuscript revision.
5	Language evaluation	<p>Classification: Grade A and two Grades B.</p> <p>No language editing certificate was provided.</p>	Thanks, the English editing certificate has been attached separately.

S. No.	Section / Content	Comment	Response
6	Re-using published images	<p>If an author of a submission is re-using a figure or figures published elsewhere, or that is copyrighted, the author must provide documentation that the previous publisher or copyright holder has given permission for the figure to be re-published; and correctly indicating the reference source and copyrights.</p> <p>For example, “Figure 1 Histopathological examination by hematoxylin-eosin staining (200 ×). A: Control group; B: Model group; C: Pioglitazone hydrochloride group; D: Chinese herbal medicine group. Citation: Yang JM, Sun Y, Wang M, Zhang XL, Zhang SJ, Gao YS, Chen L, Wu MY, Zhou L, Zhou YM, Wang Y, Zheng FJ, Li YH. Regulatory effect of a Chinese herbal medicine formula on non-alcoholic fatty liver disease. World J Gastroenterol 2019; 25(34): 5105-5119. Copyright ©The Author(s) 2019. Published by Baishideng Publishing Group Inc[6]”. And please cite the reference source in the references list.</p> <p>If the author fails to properly cite the published or copyrighted picture(s) or table(s) as described above, he/she will be subject to withdrawal of the article from BPG publications and may even be held liable.</p>	We have not reused any published images for this manuscript.
7	References	PMID and DOI numbers are missing in the reference list. Please provide the PubMed numbers and DOI citation numbers to the reference list and list all authors of the references. Please revise throughout	Thanks for the comment. We have included PMID and DOI (wherever applicable) in references.
8	References	Please revise the references according to the Format for references guidelines, and be sure to edit the reference using the reference auto-analyser.	The references have been updated in accordance with the format for references guidelines of the journal.

S. No.	Section / Content	Comment	Response
9	Author Information	Please download the Format for authorship, institution, and corresponding author guidelines, and further check if the authors names and institutions meet the requirements of the journal.	Author information including corresponding author details have been updated per the Format for Authorship, Institution, and Corresponding Author Guidelines.
10	Manuscript Information	Please check if the manuscript information is correct.	Thanks for the comment. We have thoroughly checked for the accuracy of information provided in the manuscript.
11	Footnotes and Figure Legends	<p>The authors did not provide original pictures. Please provide the original figure documents.</p> <p>Please prepare and arrange the figures using PowerPoint to ensure that all graphs or arrows or text portions can be reprocessed by the editor</p> <p>(a) Requirements for figures: Please provide decomposable Figures (whose parts are all movable and editable), organize them into a single PowerPoint file, and submit as “64343-Figures.ppt” on the system. The figures should be uploaded to the file destination of “Image File”.</p> <p>(b) Requirements for tables: Please provide decomposable Tables (whose parts are all movable and editable), organize them into a single Word file, and submit as “64343-Tables.docx” on the system. The tables should be uploaded to the file destination of “Table File”.</p>	The figure and table (1 each) have been moved out of the manuscript file and submitted separately as suggested: Figure in PPT & table in Word files.
12	Copyright	Please download the Copyright License Agreement Form. Subsequently, a PDF (scanned) version of the Copyright License Agreement Form that has been signed by all authors should be uploaded to the file destination of ‘Copyright License Agreement’.	The duly-filled (signed by both authors) Copyright License Agreement Form has been submitted separately.

S. No.	Section / Content	Comment	Response
13	Conflicts of Interest	Please download the fillable ICMJE Form for Disclosure of Potential Conflicts of Interest (PDF), and fill it in. The Corresponding Author is responsible for filling out this form. Once filled out completely, the Conflict-of-Interest Disclosure Form should be uploaded to the file destination of 'Conflict-of-Interest Disclosure Form'.	ICMJE Form for Disclosure of Potential Conflicts of Interest for both the authors have been attached separately.